We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Optimizing Hypertension Management Through Remote Monitoring: Insights from a Randomized Controlled Trial

MedXY Editorial Team•Oct 2, 2025•Cardiology
Blood Pressure Managementclinical trialHypertensionremote monitoring

Study Background and Disease Burden

Hypertension represents a significant global health challenge, affecting approximately 1.4 billion adults worldwide, according to the World Health Organization. This chronic disease is a prominent risk factor for cardiovascular events, such as heart attacks and strokes, representing a considerable burden on healthcare systems. Regular blood pressure (BP) monitoring is a crucial aspect of hypertension management, enabling timely interventions and adjustments in therapy. The advent of digital health technologies, particularly remote monitoring, offers a promising avenue for enhancing patient adherence and engagement. Nonetheless, the long-term efficacy of remote versus traditional monitoring approaches in blood pressure control necessitates more rigorous evaluation. This study aims to validate whether remote monitoring coupled with guidance can significantly improve BP outcomes compared to usual care or self-monitoring alone.

Study Design

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior StudiesDapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.Sep 22, 2026Unveiling the Role of Angiotensin II-Driven TGF-β1 in Enhancing Platelet PAR4 Expression and Thrombotic Risk in HypertensionThis study reveals that angiotensin II via TGF-β1 upregulates platelet PAR4, promoting hyperactivation and thrombosis in hypertension, with valsartan attenuating this pathway and thrombotic risk.Sep 21, 2026Intestinal Serotonergic Vagal Signaling: A Novel Link Between Gut Microbiota and Hypertension ManagementRecent research identifies intestinal serotonin 5-HT3a receptor signaling via vagal neurons as a key mediator of microbiota-induced hypertension, offering new insights into resistant hypertension and potential therapeutic targets.Sep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Impact of an AI-Powered Gamified Mobile Health Application on Blood Pressure Control in a Matched Patient Cohort
Study found that use of an AI-driven gamified mobile app integrating home blood pressure monitoring significantly improved blood pressure control compared to usual care in hypertensive patients.
Sep 17, 2026
Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE TrialThe phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensiveSep 9, 2026
Sustained Reduction of Severe Maternal Morbidity and Racial Disparities Through a Statewide Perinatal Quality CollaborativeA Louisiana statewide perinatal quality collaborative significantly reduced severe maternal morbidity related to hemorrhage and hypertension, sustained improvements across initiatives, and narrowed racial disparities, demonstrating durableSep 8, 2026